Compare Oscar Health Inc (OSCR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oscar Health Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Oscar Health Inc trades at $33.37 (market cap $10.22B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Oscar Health Inc and State Street SPDR S&P Biotech ETF are close in size by market cap, and Oscar Health Inc is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oscar Health Inc for 15 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| OSCR | XBI | |
|---|---|---|
Market Cap | $10.22B | $10.11B |
Volume | 4,123,394 | 12,903,266 |
Sector | Health | Broad Market / Factor |
52-Week High | $33.81 | $169.55 |
52-Week Low | $10.85 | $104.99 |
Typical Hold Time | 15 Days | 38 Days |
Enterprise Value | $6.57B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OSCR trades at $33.1, up 0.58% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 and Q2 2026 earnings beats, with revenue growth from $11.7B in 2025 to a projected $15.3B in 2026, turning to a net profit. Analyst consensus is a $34 price target, with 31% buy ratings. Recent news highlights market share gains and raised 2026 guidance following its Investor Day.
The outlook is positive, driven by execution in the ACA market and new growth avenues, but risks include rising medical costs threatening profitability and a high P/E ratio. The stock offers growth potential if margin expansion continues as guided.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
